07
Mar

Some of the leaders in the frenzied late-stage race to develop a PCSK9 drug watched their stock prices stumble on Friday afternoon as word of the FDA’s concern about potential neurocognitive side effects in the cholesterol drug class ripped through Twitter.

…read more

Source: UPDATED: Regeneron, Sanofi and Amgen shares suffer on FDA’s frets about PCSK9 class

    

0 No comments